Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Main, Janice
and
Thomas, Howard C.
2010.
Antibiotic and Chemotherapy.
p.
608.
Cheng, Mindy M.
Alfonso, Rafael
Best, Jennie H.
Garrison, Louis P.
Bruhn, David
and
Veenstra, David L.
2010.
The economic value of reducing medication dosing frequency with drug delivery technologies: an evidence assessment.
Journal of Medical Economics,
Vol. 13,
Issue. 2,
p.
193.
Zuure, Freke R
Heijman, Titia
Urbanus, Anouk T
Prins, Maria
Kok, Gerjo
and
Davidovich, Udi
2011.
Reasons for compliance or noncompliance with advice to test for hepatitis C via an internet-mediated blood screening service: a qualitative study.
BMC Public Health,
Vol. 11,
Issue. 1,
Townsend, Rebecca
McEwan, Phil
Kim, Ray
and
Yuan, Yong
2011.
Structural Frameworks and Key Model Parameters in Cost-Effectiveness Analyses for Current and Future Treatments of Chronic Hepatitis C.
Value in Health,
Vol. 14,
Issue. 8,
p.
1068.
Zuure, Freke R.
Davidovich, Udi
Coutinho, Roel A.
Kok, Gerjo
Hoebe, Christian J.P.A.
van den Hoek, Anneke
Jansen, Peter L.M.
van Leeuwen-Gilbert, Paula
Verheuvel, Nicole C.
Weegink, Christine J.
and
Prins, Maria
2011.
Using Mass Media and the Internet As Tools to Diagnose Hepatitis C Infections in the General Population.
American Journal of Preventive Medicine,
Vol. 40,
Issue. 3,
p.
345.
Gelman, Michael A.
and
Glenn, Jeffrey S.
2011.
Mixing the right hepatitis C inhibitor cocktail.
Trends in Molecular Medicine,
Vol. 17,
Issue. 1,
p.
34.
El Khoury, Antoine C.
Wallace, Carolyn
Klimack, William K.
and
Razavi, Homie
2012.
Economic burden of hepatitis C-associated diseases: Europe, Asia Pacific, and the Americas.
Journal of Medical Economics,
Vol. 15,
Issue. 5,
p.
887.
Salmon-Ceron, Dominique
Cohen, Julien
Winnock, Maria
Roux, Perrine
Sadr, Firouze Bani
Rosenthal, Eric
Martin, Isabelle Poizot
Loko, Marc-Arthur
Mora, Marion
Sogni, Philippe
Spire, Bruno
Dabis, François
and
Carrieri, Maria Patrizia
2012.
Engaging HIV-HCV co-infected patients in HCV treatment: the roles played by the prescribing physician and patients' beliefs (ANRS CO13 HEPAVIH cohort, France).
BMC Health Services Research,
Vol. 12,
Issue. 1,
Canavan, C.
Eisenburg, J.
Meng, L.
Corey, K.
and
Hur, C.
2013.
Ultrasound Elastography for Fibrosis Surveillance Is Cost Effective in Patients with Chronic Hepatitis C Virus in the UK.
Digestive Diseases and Sciences,
Vol. 58,
Issue. 9,
p.
2691.
Young, J.
Potter, M.
Cox, J.
Cooper, C.
Gill, J.
Hull, M.
Walmsley, S.
and
Klein, M. B.
2013.
Variation between Canadian centres in the uptake of treatment for hepatitis C by patients coinfected with HIV: a prospective cohort study.
CMAJ Open,
Vol. 1,
Issue. 3,
p.
E106.
Toy, Mehlika
2013.
Cost-effectiveness of viral hepatitis B & C treatment.
Best Practice & Research Clinical Gastroenterology,
Vol. 27,
Issue. 6,
p.
973.
McDonald, Scott A.
Hutchinson, Sharon J.
Palmateer, Norah E.
Allen, Elizabeth
Cameron, Sheila O.
Goldberg, David J.
and
Taylor, Avril
2013.
Decrease in health-related quality of life associated with awareness of hepatitis C virus infection among people who inject drugs in Scotland.
Journal of Hepatology,
Vol. 58,
Issue. 3,
p.
460.
Stahmeyer, Jona T.
Schauer, Svenja
Rossol, Siegbert
Heinrich Wedemeyer, Hans
Wirth, Daniel
Bianic, Florence
and
Krauth, Christian
2013.
Cost-effectiveness of Triple Therapy with Telaprevir for Chronic Hepatitis C Virus Patients in Germany.
Journal of Health Economics and Outcomes Research,
Vol. 1,
Issue. 3,
p.
239.
Innes, Hamish A.
Hutchinson, Sharon J.
Barclay, Stephen
Cadzow, Elaine
Dillon, John F.
Fraser, Andrew
Goldberg, David J.
Mills, Peter R.
McDonald, Scott A.
Morris, Judith
Stanley, Adrian
and
Hayes, Peter
2013.
Quantifying the Fraction of Cirrhosis Attributable to Alcohol Among Chronic Hepatitis C Virus Patients: Implications for Treatment Cost-Effectiveness.
Hepatology,
Vol. 57,
Issue. 2,
p.
451.
Cure, Sandrine
Bianic, Florence
Gavart, Sandra
Curtis, Steve
Lee, Seina
and
Dusheiko, Geoffrey
2014.
Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in treatment-experienced chronic hepatitis C genotype 1 patients.
Journal of Medical Economics,
Vol. 17,
Issue. 1,
p.
77.
Vellopoulou, Aikaterini
van Agthoven, Michel
van der Kolk, Annemarie
de Knegt, Robert J.
Berdeaux, Gilles
Cure, Sandrine
Bianic, Florence
and
Lamotte, Mark
2014.
Cost Utility of Telaprevir–PR (Peginterferon–Ribavirin) Versus Boceprevir–PR and Versus PR Alone in Chronic Hepatitis C in The Netherlands.
Applied Health Economics and Health Policy,
Vol. 12,
Issue. 6,
p.
647.
Cure, Sandrine
Bianic, Florence
Gavart, Sandra
Curtis, Steve
Lee, Seina
and
Dusheiko, Geoffrey
2014.
Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in previously untreated chronic hepatitis C genotype 1 patients.
Journal of Medical Economics,
Vol. 17,
Issue. 1,
p.
65.
Tsochatzis, Emmanuel A.
Crossan, Catriona
Longworth, Louise
Gurusamy, Kurinchi
Rodriguez-Peralvarez, Manolo
Mantzoukis, Konstantinos
O'Brien, Julia
Thalassinos, Evangelos
Papastergiou, Vassilios
Noel-Storr, Anna
Davidson, Brian
and
Burroughs, Andrew K.
2014.
Cost-effectiveness of noninvasive liver fibrosis tests for treatment decisions in patients with chronic hepatitis C.
Hepatology,
Vol. 60,
Issue. 3,
p.
832.
Zuure, Freke R
Urbanus, Anouk T
Langendam, Miranda W
Helsper, Charles W
van den Berg, Charlotte HSB
Davidovich, Udi
and
Prins, Maria
2014.
Outcomes of hepatitis C screening programs targeted at risk groups hidden in the general population: a systematic review.
BMC Public Health,
Vol. 14,
Issue. 1,
Backx, M.
Lewszuk, A.
White, J. R.
Cole, J.
Sreedharan, A.
van Sanden, S.
Diels, J.
Lawson, A.
Neal, K. R.
Wiselka, M. J.
Ito, T.
and
Irving, W. L.
2014.
The cost of treatment failure: resource use and costs incurred by hepatitis C virus genotype 1–infected patients who do or do not achieve sustained virological response to therapy.
Journal of Viral Hepatitis,
Vol. 21,
Issue. 3,
p.
208.